Description
NephroGenex, Inc. is a United States-based drug development company focusing on novel therapies for kidney disease. The Company has developed Pyridorin (pyridoxamine dihydrochloride), it targets diabetes-induced carbonyl and oxidative chemistries that are a principal causative factor in the development of diabetic nephropathy and other diabetic complications. It is conducting a new Phase 2b clinical trial (PYR-210) that is evaluating the safety and efficacy of Pyridorin in slowing the progression of overt nephropathy in patients with type 2 diabetes.
Address
4401 Research Commons Building Suite 290,
79 T.W. Alexander D P.O. Box 14188
RESEARCH TRIANGLE PARK, NC 27709-4188
United States
RESEARCH TRIANGLE PARK, NC 27709-4188
United States
Key stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -965.40% | -347.63% |
| Return on average equity | - | - |
| Employees | 3 |
No comments:
Post a Comment